Prot#RPC01-3203: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease”

Project: Research project

Project Details

StatusActive
Effective start/end date9/9/199/9/22

Funding

  • ICON Clinical Research, LLC (Prot#RPC01-3203)
  • Celgene International II Sàrl (Prot#RPC01-3203)